Subscribe
shutterstock_1216100428_gral
GrAl / Shutterstock.com
3 June 2021Big PharmaAlex Baldwin

Clarus succeeds in invalidating four Lipocine testosterone patents

Clarus Therapeutics has convinced a US court to invalidate four Lipocine testosterone booster patents it was accused of infringing.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Actavis loses testosterone patent case at Federal Circuit
17 October 2016   The US Court of Appeals for the Federal Circuit has affirmed a district court’s patent ruling in favour of global pharma company Endo and Scotland-based Strakan International in a case against Actavis.
Americas
Eli Lilly sues Cipla for infringing testosterone patents
1 November 2016   Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Actavis loses testosterone patent case at Federal Circuit
17 October 2016   The US Court of Appeals for the Federal Circuit has affirmed a district court’s patent ruling in favour of global pharma company Endo and Scotland-based Strakan International in a case against Actavis.
Americas
Eli Lilly sues Cipla for infringing testosterone patents
1 November 2016   Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron.

More on this story

Americas
Actavis loses testosterone patent case at Federal Circuit
17 October 2016   The US Court of Appeals for the Federal Circuit has affirmed a district court’s patent ruling in favour of global pharma company Endo and Scotland-based Strakan International in a case against Actavis.
Americas
Eli Lilly sues Cipla for infringing testosterone patents
1 November 2016   Eli Lilly has filed a complaint against India-based drug company Cipla for allegedly infringing its patents covering Axiron.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility